Allulose epimerase variant with excellent thermal stability, its preparation method, and the preparation method of allulose using it.

By substituting amino acids and recombinantly expressing D-allulose 3-epimerase derived from *Fusobacterium previae*, the prepared allulose epimerase variant W29K/A77S/G216S/M234I exhibited high conversion rate and stability at high temperatures, solving the problem of insufficient conversion rate and stability in existing technologies, and is suitable for the industrial production of allulose.

CN116917481BActive Publication Date: 2026-11-10DAESANG CORP
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202180084320.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-11-19
Filing Date
2021-11-22
Publication Date
2026-11-10
Estimated Expiration
2041-11-22

AI Technical Summary

Technical Problem

Existing wild-type D-allulose 3-epimerase derived from microorganisms has a low conversion rate from fructose to allulose, low thermal stability, and is not suitable for industrialization.

Method used

A novel allulose epimerase variant, W29K/A77S/G216S/M234I, was prepared by substituting specific amino acid residues into the amino acid sequence of wild-type D-allulose 3-epimerase derived from *Fusobacterium proliferae*. The enzyme was then expressed and purified using a recombinant vector to improve its conversion efficiency and thermostability.

Benefits of technology

It achieves high conversion activity and good thermal stability under high temperature conditions, making it suitable for the industrial production of allulose and reducing production costs and time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116917481B_ABST
    Figure CN116917481B_ABST
Patent Text Reader

Abstract

This invention provides a novel allulose epimerase variant in which an amino acid residue at a specific position in the amino acid sequence of wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii* is replaced by another amino acid residue, and its various uses. Compared to wild-type D-allulose 3-epimerase or the D-allulose epimerase variant W29K / G216S / M234I derived from *Flavonifractor plautii*, this novel allulose epimerase variant exhibits high activity in the conversion from fructose to allulose, and particularly excellent thermal stability at temperatures above 60°C. Therefore, when performing industrial-scale enzymatic conversion reactions for the mass production of allulose, it can prevent contamination, shorten production time, and reduce production costs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to allulose epimerase variants, and more specifically to allulose epimerase variants that exhibit improved fructose-to-allulose conversion efficiency and thermal stability compared to D-allulose 3-epimerase derived from *Flavonifractor plautii*, and various inventions derived therefrom. Background Technology

[0002] D-allulose, an epimer of fructose (carbon 3), is also known as D-psicose. Compared to sugar, D-allulose has 70% of the sweetness (Oshima 2006) but only 0.3% of the energy, making it a functional monosaccharide suitable as a low-calorie sweetener in weight-loss foods (Matsuo et al., 2002). Furthermore, D-allulose has the function of absorbing glucose and inhibiting blood sugar, making it applicable to diabetic diets and health-promoting foods. It can also inhibit the accumulation of abdominal fat by suppressing the activity of enzymes involved in lipid synthesis in the liver, thus making it suitable for various functional foods such as health supplements (Matsuo et al. 2001; Iida et al. 2008; Hayashi et al. 2010; Hossain et al. 2011).

[0003] Due to the characteristics described above, allulose is a preferred raw material to replace sugar. However, as a rare monosaccharide found very little in nature, an efficient method for its production is needed for its application in the food industry. Existing allulose production methods primarily involve chemical processes. Bilik et al. proposed a method utilizing the catalytic action of molybdate ions to convert fructose into allulose. McDonald produced allulose from 1,2:4,5-di-δ-isopropylidene-beta-D-fructopyranose through a three-step chemical process. Furthermore, Doner produced allulose by heating fructose with ethanol and trimethylamine. However, these chemical production methods suffer from high costs, low efficiency, and the generation of numerous byproducts.

[0004] As a biological method for allulose production, a proposed approach (Ken Izumori) utilizes microbial cellular reactions to produce allulose from galactitol, D-tagatose, or D-tarottitol. However, this method relies on rare sugars as substrates, making it difficult to apply to industrial production. The most effective method for industrialization is to identify enzymes from the D-ketose 3-epimerase group that convert fructose to allulose. Existing publications describe the use of D-tagatose 3-epimerases derived from *Clostridium fibrinolyticum* H(10) (Mu et al. 2011), *Agrobacterium tumefaciens* (Kim et al. 2006), *Pseudomonas chicory* (Itoh et al. 1994), and *Rhizobium coli* (Zhang et al. 2009) after intercalation into *Escherichia coli*, followed by the production of allulose from fructose using the D-tagatose 3-epimerase expressed in the transformed *E. coli*.

[0005] Related to the technology of producing allulose from fructose using enzymes, Korean Patent Publication No. 10-0744479 discloses a method for producing allulose using an allulose epimerase derived from *Agrobacterium tumefaciens*; Korean Patent Publication No. 10-0832339 discloses *Sinorhizobium* YB-58 KCTC 10983BP, which has activity in converting fructose to allulose, and a method for converting fructose to allulose using it; Korean Patent Publication No. 10-1106253 discloses *Escherichia coli* containing a polynucleotide encoding an allulose 3-epimerase of *Agrobacterium tumefaciens* C58, which has activity in catalyzing the conversion from fructose to allulose, and a method for producing allulose from fructose using it; and Korean Patent Publication No. 10-1339443 discloses an allulose production method using an allulose epimerase derived from *Agrobacterium* genus. Korean Patent Publication No. 10-1318422 discloses a ketose 3-epimerase derived from *Clostridium scindens* and a method for producing allulose from fructose using it. Korean Patent Publication No. 10-1473918 also discloses a D-allulose 3-epimerase derived from *Flavonifractor plautii* and a method for producing allulose from fructose using it.

[0006] However, for wild-type D-allulose 3-epimerases derived from microorganisms, the conversion rate from fructose to allulose is low, the thermal stability is poor, and the inactivation rate at the optimal activity temperature is rapid, making them unsuitable for industrialization. Therefore, it is necessary to develop new D-allulose 3-epimerase variants that offer improved conversion rates or thermal stability from fructose to allulose compared to wild-type D-allulose 3-epimerases derived from microorganisms. Related to the D-allulose 3-epimerase variant, Korean Patent Publication No. 10-2014-0021974 discloses a D-allulose 3-epimerase derived from the original Cypriniform ZAS-1 that exhibits stability by inducing mutations at the gene level to accelerate allulose conversion at high temperatures. Korean Patent Publication No. 10-1203856 discloses an allulose epimerase variant with improved thermal stability obtained by mutation of wild-type allulose epimerase derived from Agrobacterium tumefaciens. Furthermore, Korean Patent Publication No. 10-2254411 discloses a novel allulose epimerase variant in which glycine (Gly) at position 216 of the amino acid sequence of wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii* is replaced by serine (Ser). Korean Patent Publication No. 10-2021-0132405 discloses a novel allulose epimerase variant in which tryptophan (Trp) at position 29 of the amino acid sequence of wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii* is replaced by lysine (Lys), glycine (Gly) at position 216 is replaced by serine (Ser), and methionine (Met) at position 234 is replaced by isoleucine (Ile). Summary of the Invention

[0007] Technical issues

[0008] The present invention is derived from the prior art, and its first objective is to provide a novel D-allulose 3-epimerase variant that exhibits improved fructose-to-allulose conversion efficiency and thermal stability compared to wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii*.

[0009] A second object of the present invention is to provide a method for preparing novel D-allulose 3-epimerase variants or a variety of factors required for preparing novel D-allulose 3-epimerase variants.

[0010] A third object of the present invention is to provide a method for preparing allulose from fructose or the various factors required for preparing allulose from fructose.

[0011] Technical solution

[0012] The applicant of this invention previously filed a patent application for a novel allulose epimerase variant in which the glycine residue at position 216 of the amino acid sequence of wild-type D-allulose 3-epimerase derived from *Flavon* is replaced by serine, and was granted [Korean Patent Publication No. 10-2254411 (May 14, 2021)]. A novel allulose epimerase variant of wild-type D-allulose 3-epimerase of *ifractorplautii*, in which tryptophan (Trp) at position 29 is replaced by lysine (Lys), glycine (Gly) at position 216 is replaced by serine (Ser), and methionine (Met) at position 234 is replaced by isoleucine (Ile) [Korean Patent Publication No. 10-2021-0132405 (2021.11.04)]. The allulose epimerase variants disclosed in Korean Patent Publication No. 10-2254411 and Korean Patent Publication No. 10-2021-0132405 exhibit improved thermal stability compared to the wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii*. However, when the conversion reaction from fructose to allulose is carried out at high temperatures above 60°C for an extended period, the enzyme activity decreases, indicating that further improvements are needed from an industrialization perspective for the large-scale production of allulose. In order to improve the conversion rate and thermal stability of the allulose epimerase variant disclosed in Korean Patent Publication No. 10-2021-0132405 from fructose, the inventors of this invention used protein structure prediction technology to additionally derive and predict candidate amino acid residue positions related to improving conversion rate and thermal stability. They confirmed that the conversion rate and thermal stability from fructose are improved only when an amino acid residue at a specific position is replaced by another amino acid residue, thus completing this invention.

[0013] To achieve the first objective mentioned above, the present invention provides an allulose epimerase variant formed from the amino acid sequence of sequence number 5.

[0014] To address the second objective mentioned above, the present invention provides a polynucleotide encoding an allulose epimerase variant formed from the amino acid sequence of Serial Number 5. Furthermore, the present invention provides a recombinant vector comprising the polynucleotide encoding the allulose epimerase variant formed from the amino acid sequence of Serial Number 5. Furthermore, the present invention provides the polynucleotide encoding the allulose epimerase variant formed from the amino acid sequence of Serial Number 5, or a recombinant strain transformed using a recombinant vector containing the aforementioned polynucleotide. Furthermore, the present invention provides a method for preparing an allulose epimerase variant, comprising: culturing a recombinant strain transformed using the polynucleotide encoding the allulose epimerase variant formed from the amino acid sequence of Serial Number 5, or a recombinant vector containing the aforementioned polynucleotide, to express the allulose epimerase variant; and isolating the allulose epimerase variant from the fragments of the recombinant strain expressing the aforementioned allulose epimerase variant.

[0015] To achieve the third objective mentioned above, the present invention provides a composition for producing allulose comprising an allulose epimerase variant formed from the amino acid sequence of Serial Number 5. Furthermore, the present invention provides a composition for producing allulose using a polynucleotide encoding an allulose epimerase variant formed from the amino acid sequence of Serial Number 5, or a recombinant strain transformed with a recombinant vector containing the aforementioned polynucleotide, a culture containing the aforementioned recombinant strain, or a fragment of the aforementioned recombinant strain. Furthermore, the present invention provides a method for preparing allulose comprising the step of reacting fructose with an allulose epimerase variant formed from the amino acid sequence of Serial Number 5, or a composition containing the aforementioned allulose epimerase variant. Furthermore, the present invention provides a method for preparing allulose comprising the step of reacting fructose with a recombinant strain transformed with a polynucleotide encoding an allulose epimerase variant formed from the amino acid sequence of Serial Number 5, or a recombinant strain transformed with a recombinant vector containing the aforementioned polynucleotide, a culture containing the aforementioned recombinant strain, a fragment of the aforementioned recombinant strain, or a composition thereof.

[0016] The effects of the invention

[0017] The novel allulose epimerase variant of this invention exhibits higher activity in the conversion from fructose to allulose compared to wild-type D-allulose 3-epimerase or D-allulose epimerase variant W29K / G216S / M234I derived from *Flavonifractor plautii*. Furthermore, it demonstrates excellent thermal stability, particularly at temperatures above 60°C. Therefore, when performing industrial-scale enzymatic conversion reactions for the mass production of allulose, contamination can be prevented, production time can be shortened, and production costs can be reduced. Attached Figure Description

[0018] Figure 1 This indicates that the inventors of this invention selected four amino acid residue positions as substitution candidates in order to improve the conversion rate from fructose to allulose and the thermal stability of the D-allulose epimerase variant W29K / G216S / M234I. Detailed Implementation

[0019] The present invention will now be described in detail.

[0020] One embodiment of the present invention relates to a novel D-allulose 3-epimerase variant (hereinafter referred to as "allulose epimerase variant") capable of converting fructose into allulose. In the allulose epimerase variant W29K / A77S / G216S / M234I of one example of the present invention, tryptophan (Trp) at position 29 of the amino acid sequence (Sequence No. 1) of the wild-type D-allulose 3-epimerase derived from *Flavonifractorplautii* is replaced by lysine (Lys), alanine (Ala) at position 77 is replaced by serine (Ser), glycine (Gly) at position 216 is replaced by serine (Ser), and methionine (Met) at position 234 is replaced by isoleucine (Ile). The allulose epimerase variant W29K / A77S / G216S / M234I of the present invention exhibits higher fructose-to-allulose conversion activity compared to wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii* or its variant W29K / G216S / M234I, and also demonstrates excellent thermal stability, especially at high temperatures above 60°C. In the aforementioned D-allulose 3-epimerase variant W29K / G216S / M234I, the tryptophan (Trp) at position 29 of the amino acid sequence (Sequence No. 1) of the wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii* is replaced by lysine (Lys), the glycine (Gly) at position 216 is replaced by serine (Ser), and the methionine (Met) at position 234 is replaced by isoleucine (Ile), forming the amino acid sequence of Sequence No. 3. The preparation method and characteristics are disclosed in Korean Patent Publication No. 10-2021-0132405.The allulose epimerase variant W29K / A77S / G216S / M234I can be obtained by the following method: A polynucleotide encoding W29K / G216S / M234I, a variant of wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii*, is used as a template. Polymerase chain reaction (PCR) is performed using oligonucleotides with a specified base sequence as primer pairs. Then, the amplified variant fragment is used as a template, and overlap extension PCR is performed using oligonucleotides containing the restriction enzyme recognition site as primers. A recombinant expression vector is prepared by inserting a polynucleotide fragment containing an encrypted amino acid sequence of the allulose epimerase variant into the expression vector. The host strain is then transformed using this recombinant expression vector to prepare a recombinant strain, which is then cultured for expression. Furthermore, the polynucleotide encoding the aforementioned D-allulose 3-epimerase variant W29K / G216S / M234I (formed by the base sequence of Serial No. 4) can be prepared by using a polynucleotide encoding the wild-type D-allulose 3-epimerase from *Flavonifractor plautii* (formed by the base sequence of Serial No. 2) as a template, performing PCR with oligonucleotides having a specified base sequence as primer pairs, and then using the amplified variant fragment pair as a template, performing overlap extension PCR with oligonucleotides containing the sequence of the restriction enzyme recognition site as primers. The allulose epimerase variant W29K / A77S / G216S / M234I of the present invention is formed by the amino acid sequence of Serial No. 5, but the equivalent range of the allulose epimerase variant W29K / A77S / G216S / M234I of the present invention is not necessarily limited to this. For example, as long as the activity of converting fructose to allulose is maintained and the thermal stability is maintained at temperatures above 60°C, the equivalent range of the allulose epimerase variant W29K / A77S / G216S / M234I of the present invention can be a partial substitution, insertion, and / or deletion of amino acids in the amino acid sequence of sequence number 5. Preferably, the substitution of the above-mentioned amino acids is achieved by conservative amino acid replacement that does not change the properties of the protein. Furthermore, the modification of the above-mentioned amino acids can be achieved by glycosylation, acetylation, phosphorylation, etc. Furthermore, the equivalent range of the allulose epimerase variant W29K / A77S / G216S / M234I of the present invention can include proteins whose structural stability to heat, pH, etc., is increased or whose conversion activity from fructose to allulose is increased through variations or modifications in the amino acid sequence.Furthermore, the equivalence range of the allulose epimerase variant W29K / A77S / G216S / M234I of the present invention may include an amino acid sequence having 70% or more, 80% or more, 90% or more, 95% or more, or 99% or more homology with one of the amino acid sequences in sequence number 5.

[0021] Another embodiment of the present invention relates to a method for preparing a novel allulose epimerase variant W29K / A77S / G216S / M234I, or to various factors required for preparing the novel allulose epimerase variant W29K / A77S / G216S / M234I. The various factors required for preparing the aforementioned novel allulose epimerase variant W29K / A77S / G216S / M234I include polynucleotides, primer pairs, recombinant vectors, recombinant strains, etc.

[0022] The aforementioned polynucleotide is a polynucleotide encoding an allulose epimerase variant formed by the amino acid sequence of Serial Number 5, preferably formed by the base sequence of Serial Number 9. The term "polynucleotide" as used in this invention means all non-modified or modified polynucleotides (RNAs) or polydeoxyribonucleic acid (DNAs). The aforementioned polynucleotides include, but are not limited to, single-stranded or double-stranded DNA, DNA as a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, RNA as a mixture of single-stranded and double-stranded regions, or mixtures thereof. Furthermore, the equivalent range of the polynucleotide encoding the aforementioned allulose epimerase variant includes sequences substantially identical to the base sequence of Serial Number 9. The aforementioned substantial homology means that the sequence of sequence number 9 is arranged to correspond to any other sequence to the greatest extent possible, and the sequence analysis shows that the other sequence has more than 70%, more than 90%, or more than 98% sequence homology with the sequence of sequence number 9. Those skilled in the art will readily understand that by using gene recombination techniques known in the art to substitute, add, or delete one or more bases in the aforementioned polynucleotide sequence, a polynucleotide that denatures an allulose epimerase variant with the same activity within the range of the aforementioned substantial homology can be prepared. This comparison of homology can be performed using commercially available computer programs to calculate the homology between two or more sequences as a percentage (%).

[0023] Furthermore, the primer pair described above is used to synthesize a polynucleotide encoding an allulose epimerase variant formed by the amino acid sequence of sequence number 5. When the polynucleotide encoding W29K / G216S / M234I, which is a variant of D-allulose 3-epimerase (formed by the base sequence of sequence number 4), is used as a template, it consists of a forward primer and a reverse primer having the following base sequences.

[0024] A77S

[0025] *Forward primer base sequence (5'→3')

[0026]

[0027] *Reverse primer base sequence (5'→3')

[0028]

[0029] Furthermore, the recombinant vector contains a polynucleotide encoding an allulose epimerase variant formed by the amino acid sequence of sequence number 5. The recombinant vector provides a morphological configuration for inserting the polynucleotide encoding the allulose epimerase variant into a cloning vector or expression vector using known standard methods. The term "cloning vector" as used in this invention is defined as a substance that transfers a DNA fragment into a host cell and can reproduce it. The cloning vector in this invention may also contain a polyadenylation signal, a transcription termination sequence, and a multiple cloning site. In this case, the multiple cloning site contains at least one endonuclease restriction site. Furthermore, the cloning vector may also contain a promoter. As an example, the polynucleotide encoding the allulose epimerase variant W29K / A77S / G216S / M234I in this invention can be located upstream of both the polyadenylation signal and the transcription termination sequence. Furthermore, the term "expression vector" as used in this invention is defined by the DNA sequence required for the transcription and translation of DNA cloned within a suitable host. Also, the term "expression vector" as used in this invention means a gene fabrication that includes the necessary regulatory factors that enable the expression of the insert in a manner that is readily connected to the insert when present within the cells of an individual. The aforementioned expression vectors can be prepared and purified using standard recombinant DNA techniques. The type of expression vector is not particularly limited as long as it functions to express the desired gene and produce the desired protein in various host cells, including prokaryotic and eukaryotic cells, but vectors that maintain a robust promoter activity and strong expression capacity while allowing for the mass production of exogenous proteins with a morphology similar to that in their natural state are preferred. The expression vector preferably contains at least a promoter, a start codon, a gene encoding the desired protein, and a stop codon terminator. In addition, it may appropriately include DNA encoding the signal peptide, additional expression regulatory sequences, untranslated regions on the 5' and 3' sides of the desired gene, selection marker regions, or reproducible units. A "promoter" signifies a minimal sequence sufficient to indicate transcription. Furthermore, the aforementioned promoters may contain a promoter structure sufficient for the expression of a cell-type-specific or externally induced, promoter-dependent gene, which may be located in the 5' or 3' portion of the gene. All of the aforementioned promoters include conserved promoters and inducible promoters.The promoter sequence may be derived from prokaryotes, eukaryotes, or viruses. The term "promotablely linked" as used in this invention means that one function is regulated by another due to the association of polynucleotide sequences on a single polynucleotide. For example, when the promoter controls the expression of the coding sequence (i.e., the coding sequence is under the transcriptional regulation of the promoter), when the promoter is linked to the coding sequence for initiation, or when the ribosome-binding site promotes translation, the ribosome-binding site is linked to the coding sequence for initiation. The coding sequence may be linked to the regulatory sequence for initiation in either a sense or antisense direction. The recombinant vector of this invention is preferably an expression vector.

[0030] Furthermore, the aforementioned recombinant strains are transformed using a polynucleotide encoding an allulose-to-isomerase variant formed from the amino acid sequence of sequence number 5, or using a recombinant vector containing the aforementioned polynucleotide. As used in this invention, the term "recombinant strain" means a cell transformed by introducing a polynucleotide encoding one or more target proteins or an expression vector containing such a polynucleotide into a host cell. Methods for preparing transformants by introducing the aforementioned expression vectors into host cells include, but are not limited to, transient transfection, microinjection, transduction, cell fusion, calcium phosphate precipitation, liposome-mediated transfection, DEAE-Dextran-mediated transfection, polybrene-mediated transfection, electroporation, electroinjection, chemical treatment methods such as polyethylene glycol (PEG), methods using a gene gun, and heat shock methods. In this invention, the host cell that can be converted into an expression vector can be any host known in the field, such as prokaryotic cells, plant cells, insect cells, or animal cells, and its species is not greatly limited. Preferably, a host with high DNA introduction efficiency and high expression efficiency of the introduced DNA is used. For example, the host cell can be *Escherichia coli*. *E. coli* strains include BL21, JM109, K-12, LE392, RR1, DH5α, or W3110, but are not limited to these. Furthermore, as the host cell, strains selected from the group consisting of *Bacillus subtilis*, *Bacillus thuringiensis*, *Corynebacterium glutamicum*, *Salmonella typhimurium*, other *Serratia marcescens* strains, and various *Pseudomonas* strains can be used.

[0031] Furthermore, the preparation method of the aforementioned allulose epimerase variant W29K / A77S / G216S / M234I includes the following steps: culturing a recombinant strain that expresses the allulose epimerase variant by transforming it with a polynucleotide encoding the allulose epimerase variant formed by the amino acid sequence of sequence number 5, or by transforming it with a recombinant vector containing the aforementioned polynucleotide; and isolating the pistose epimerase from the fragments of the recombinant strain expressing the allulose epimerase variant. Expression of the protein using host cells can be induced using lactose, isopropyl-1-thio-β-D-galactopyranoside (IPTG) as an inducing factor, and the induction time can be adjusted to maximize the amount of protein. In this invention, the allulose epimerase variant can be recovered from the fragments of the recombinant strain. Cells used for protein expression can be destroyed by repeated freezing and thawing, sonication, mechanical damage, or various substances or chemicals such as cell-degrading agents. They can be separated or purified using conventional biochemical separation techniques (Sambrook et al., Molecular Cloning: A laborarory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989; Deuscher, M., Guide to Protein Purification Methods Enzymology, Vol. 182. Academic Press. Inc., San Diego, CA, 1990). For example, methods for separating or purifying proteins expressed using host cells include, but are not limited to, electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography (ion exchange chromatography, affinity chromatography, immunoadsorption affinity chromatography, reversed-phase HPLC, gel permeation HPLC), isoelectric focusing, and various variations or combinations thereof. On the other hand, the step of separating allulose epimerase variants from the fragments of recombinant strains in this invention is preferably performed using peptide-tagged affinity chromatography. The peptide tags mentioned above can use a variety of well-known tags such as HA tag, FLAG tag, His tag, biotin carboxyl carrier protein (BCCP), c-myc tag, V5 tag, glutathione S-transferase (GST) or maltose binding protein (MBP), among which the His tag is preferred.His-tagged proteins are specifically captured on Ni-NTA (nickel-nitrotriacetic acid) resin columns and can be dissolved using ethylenediaminetetraacetic acid (EDTA) or imidazole.

[0032] Another embodiment of the present invention relates to a method for preparing allulose from fructose or to various factors required for preparing allulose from fructose. Among the various factors required for preparing allulose from the aforementioned fructose are allulose production compositions.

[0033] One example of the allulose production composition described above includes an allulose epimerase variant W29K / A77S / G216S / M234I formed from the amino acid sequence of Serial No. 5. Another example of the allulose production composition described above includes a recombinant strain transformed using a polynucleotide encoded by the allulose epimerase variant formed from the amino acid sequence of Serial No. 5, or transformed using a recombinant vector containing the aforementioned polynucleotide, a culture of the aforementioned recombinant strain, or a fragment of the aforementioned recombinant strain. In this case, the allulose production composition preferably further includes one or more ions selected from the group consisting of manganese ions, nickel ions, and cobalt ions, and more preferably includes manganese ions or nickel ions. The novel allulose epimerase variant of the present invention exhibits metalloenzyme characteristics, where the activity is regulated by metal ions. By performing the reaction utilizing the enzyme in the presence of specific metal ions such as manganese ions or nickel ions, the production yield of allulose can be increased.

[0034] Furthermore, one example of a method for preparing allulose from fructose includes the step of reacting fructose with a polynucleotide encoded by an allulose epimerase variant formed from the amino acid sequence of sequence number 5, or with a recombinant strain transformed using a recombinant vector containing the aforementioned polynucleotide, a culture of the aforementioned recombinant strain, a fragment of the aforementioned recombinant strain, or a composition containing one or more of these. The method for preparing allulose from fructose may also include the step of adding metal ions, the types of which are as described above. As an example, the metal ions may be added to fructose as a substrate, or to a mixture of the enzyme variant and fructose. As another example, the metal ions may be added to a carrier in which the enzyme variant is immobilized (before adding fructose), or to a mixture of the carrier in which the enzyme variant is immobilized and fructose (after adding fructose), or added in the form of fructose and a mixture when fructose is added. When using a recombinant strain, the metal ions may be added to the culture or cultured in a medium containing metal ions. Furthermore, in the method for preparing allulose from the aforementioned fructose, the allulose epimerase variant or the aforementioned recombinant strain is preferably immobilized onto a vector. This vector creates an environment that can maintain the activity of the immobilized enzyme for a long period and can be selected from any known vector suitable for enzyme immobilization. For example, sodium alginate can be used as the vector. Sodium alginate is a natural colloidal polysaccharide abundant in the cell walls of seaweed, composed of β-D-mannuronic acid and α-L-guluronic acid, randomly forming β-1,4 bonds in terms of content, which can stably immobilize strains or enzymes and is beneficial for allulose yield. As an example, to further improve the allulose yield, a sodium alginate solution with a concentration of 1.5 to 4.0% (w / v) (e.g., an aqueous sodium alginate solution), preferably about 2.5% (w / v), can be used for the immobilization of the recombinant strain. Furthermore, in the method for preparing allulose from fructose described above, the reaction temperature is 60–70°C, preferably 60–67°C, and more preferably 60–65°C when considering the stability and maximum activity of the enzyme variant. The reaction pH is 6.5–8, preferably 6.5–7.5, and more preferably 6.5–7. In addition, the concentration of fructose in the method for preparing allulose from fructose described above is not particularly limited, but when considering productivity or economy, it is preferably 1–75% (w / w) based on the total reactants, and more preferably 4–35% (w / w). Furthermore, the concentration of the enzyme variant used in the method for preparing allulose from fructose described above can be 0.001–0.5 mg / ml based on the total reactants, preferably 0.01–0.2 mg / ml, and more preferably 0.02–0.1 mg / ml.Furthermore, when preparing allulose from fructose using recombinant strains, the host strain of the recombinant strain is preferably a food-safe strain. A food-safe strain means a strain that is generally accepted as safe (GRAS), such as strains from the genera *Saccharomyces*, *Bacillus*, and *Corynebacterium*. These strains are industrial microorganisms with various applications in the production of chemical substances for feed, pharmaceuticals, and food. Such strains are easy to genetically manipulate and culture in large quantities, or exhibit high stability under various processing conditions. Moreover, these strains maintain a relatively rigid cell membrane structure compared to other bacteria, thus exhibiting the biological characteristic of maintaining a stable cell state even under the influence of osmotic pressure caused by high sugar concentrations. Specific examples of strains that are generally accepted as safe (GRAS) include Saccharomyces cerevisiae, Bacillus subtilis, and Corynebacterium glutamicum.

[0035] The present invention will be described in more detail below through embodiments. However, the following embodiments are only used to clearly illustrate the technical features of the present invention and do not limit the scope of protection of the present invention.

[0036] Example 1: Further exploration of amino acid substitution positions to improve the conversion rate and thermostability of D-allulose 3-epimerase

[0037] In order to improve the conversion rate and thermal stability of fructose to allulose in wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii*, the applicant of this invention previously filed a patent application for a new D-allulose epimerase variant, W29K / G216S / M234I, in which tryptophan (Trp) at position 29 of the amino acid sequence of wild-type D-allulose 3-epimerase is replaced by lysine (Lys), glycine (Gly) at position 216 is replaced by serine (Ser), and methionine (Met) at position 234 is replaced by isoleucine (Ile). The wild-type D-allulose 3-epimerase derived from *Flavonifractor plautii* is formed by the amino acid sequence of Serial No. 1, and the encrypted polynucleotide fragment of the wild-type D-allulose 3-epimerase is formed by the base sequence of Serial No. 2. Furthermore, the D-allulose epimerase variant W29K / G216S / M234I is formed by the amino acid sequence of Serial No. 3, and the encrypted polynucleotide fragment of the D-allulose epimerase variant W29K / G216S / M234I is formed by the base sequence of Serial No. 4.

[0038] To improve the conversion rate and thermostability of the D-allulose epimerase variant W29K / G216S / M234I from fructose, the inventors of this invention used homology modeling techniques to predict protein structure and explore amino acid substitution positions based on the amino acid sequence of the variant. The homology modeling was performed using the Robbetta server, and the protein structure prediction and analysis were performed using software programs such as Coot, PyMol, and UCSF Chimera. When analyzing changes in chemical bonds using the three-dimensional structural model of the D-allulose epimerase variant W29K / G216S / M234I, four amino acid residue positions predicted to be related to improved conversion rate and thermostability, along with the amino acid residues that would be substituted at these positions, were selected.

[0039] Figure 1 This indicates that the inventors of this invention selected four amino acid residue positions as substitution candidates in order to improve the conversion rate from fructose to allulose and the thermal stability of the D-allulose epimerase variant W29K / G216S / M234I. Figure 1In the sequence number 3, “A77” represents alanine (Ala) at position 77, “E173” represents glutamic acid (Glu) at position 173, “W209” represents tryptophan (Trp) at position 209, and “Q240” represents glutamine (Gln) at position 240.

[0040] Furthermore, as described later, the enzyme variant W29K / A77S / G216S / M234I, formed from the amino acid sequence of sequence number 5, was prepared by replacing alanine (Ala) at position 77 of the amino acid sequence of sequence number 3 with serine (Ser). Similarly, the enzyme variant W29K / E173A / G216S / M234I, formed from the amino acid sequence of sequence number 6, was prepared by replacing glutamic acid (Glu) at position 173 of the amino acid sequence of sequence number 3 with alanine (Ala). I. Replace tryptophan (Trp) at position 209 in the amino acid sequence of sequence number 3 with leucine (Leu) to create an enzyme variant W29K / W209L / G216S / M234I formed from the amino acid sequence of sequence number 7. Replace glutamine (Gln) at position 240 in the amino acid sequence of sequence number 3 with aspartic acid (Asp) to create an enzyme variant W29K / G216S / M234I / Q240D formed from the amino acid sequence of sequence number 8.

[0041] Example 2: Preparation of recombinant vector and recombinant strain for overexpression of D-allulose 3-epimerase variant from *Flavonifractor plautii*.

[0042] Based on the polynucleotide (Sequence No. 4) of the D-allulose epimerase variant W29K / G216S / M234I, an encrypted polynucleotide fragment was prepared using the overlap extension polymerase chain reaction method to encrypt the amino acid sequences of four enzyme variants (W29K / A77S / G216S / M234I, W29K / E173A / G216S / M234I, W29K / W209L / G216S / M234I, and W29K / G216S / M234I / Q240D).

[0043] First, to prepare the gene encoding the allulose epimerase variant from *Flavonifractor plautii*, PCR was performed using the primers shown in Table 1 below. Specifically, 1 pM of oligonucleotides used as primers in Table 1 were mixed with 100 μM of deoxyribonucleoside triphosphates (dATP, dCTP, dGTP, dTTP) in a reaction solution containing 100 μM of deoxyribonucleoside triphosphates (dATP, dCTP, dGTP, dTTP), and 100 ng of a polynucleotide (serial number 4) of the D-allulose epimerase variant W29K / G216S / M234I (as template) was used as a template. The PCR reaction was performed for 25–30 cycles using a thermal cycler (TP600, TAKARA BIO Inc., Japan) in the presence of 1 unit of pfu-X DNA polymerase mixture (Bioneer).

[0044] Table 1

[0045]

[0046] After amplifying the variant fragments using primer pairs, each pair was used as a template. Oligonucleotides containing sequences indicating NdeI and XhoI restriction enzyme recognition sites were then used as primers for overlap extension PCR to ultimately produce polynucleotide fragments that encrypted the amino acid sequences of four enzyme variants (W29K / A77S / G216S / M234I, W29K / E173A / G216S / M234I, W29K / W209L / G216S / M234I, and W29K / G216S / M234I / Q240D). Table 2 below shows the base sequences of the primers used to introduce the restriction enzyme recognition sites.

[0047] Table 2

[0048]

[0049] The base sequence of sequence number 9 represents a polynucleotide fragment with encrypted amino acid sequence of enzyme variant W29K / A77S / G216S / M234I; the base sequence of sequence number 10 represents a polynucleotide fragment with encrypted amino acid sequence of enzyme variant W29K / E173A / G216S / M234I; the base sequence of sequence number 11 represents a polynucleotide fragment with encrypted amino acid sequence of enzyme variant W29K / W209L / G216S / M234I; and the base sequence of sequence number 12 represents a polynucleotide fragment with encrypted amino acid sequence of enzyme variant W29K / G216S / M234I / Q240D. The base sequences of sequences 9 to 12 consist of base sequences directly corresponding to the amino acid sequence of the enzyme variant; for convenience, the sequence of the restriction enzyme recognition site is omitted.

[0050] Subsequently, using restriction enzymes NdeI and XhoI, the prepared polynucleotide fragments were inserted into the same restriction enzyme site of pET28a (Novagen), which served as the expression vector, to prepare four recombinant expression vectors. Then, using a heat shock method (refer to Sambrook and Russell: Molecular Cloning), the recombinant expression vectors were transformed into *E. coli* BL21(DE3) (Invitrogen) to prepare four recombinant *E. coli* strains. The prepared recombinant *E. coli* strains were added to a 60% glycerol solution and frozen at -70°C before culture for enzyme expression.

[0051] Example 3: Expression and purification of a D-allulose 3-epimerase variant derived from *Flavonifractor plautii*

[0052] One ml of the recombinant E. coli prepared in Example 2 was inoculated into a 1L flask containing 150 ml of protein expression medium with the composition shown in Table 3 below (based on 1L of medium). The flask was cultured for 24 hours using a shaking incubator while maintaining a temperature of 32°C and a shaking speed of 140 rpm. Overexpression of the allulose epimerase variant was induced using 1% lactose contained in the medium.

[0053] Table 3

[0054]

[0055] The overexpressed allulose epimerase variant was then isolated using the following method: First, the culture medium of recombinant *E. coli* was centrifuged at 4100 × g and 4 °C for approximately 15 minutes to remove the supernatant, and the recombinant *E. coli* cells were recovered. Next, the recovered recombinant *E. coli* cells were resuspended in lysis buffer (containing 50 mM potassium dihydrogen phosphate, 300 mM potassium chloride, and 5 mM imidazole) and then the cells were lysed using a sonicator. The cell lysate was then centrifuged at 15814 × g and 4 °C for approximately 10 minutes to remove cell particles, and only the supernatant was recovered. Finally, a purified enzyme solution containing the allulose epimerase variant was separated from the recovered supernatant using a histidine-tag affinity chromatography column and a desalting column.

[0056] Example 4: Confirmation of the conversion rate from fructose to allulose and the thermal stability of the D-allulose 3-epimerase variant

[0057] To confirm the conversion rate and thermal stability of fructose to allulose in the D-allulose epimerase variant W29K / G216S / M234I [Korean Patent Publication No. 10-2021-0132405 (November 4, 2021)] of the applicant's previous patent application and the four newly prepared D-allulose epimerase variants (W29K / A77S / G216S / M234I, W29K / E173A / G216S / M234I, W29K / W209L / G216S / M234I, W29K / G216S / M234I / Q240D) of this invention, the enzymes were exposed to high temperature for a specified time, and the degree of reduction in fructose to allulose conversion activity was analyzed. Specifically, the W29K / G216S / M234I purified enzyme solution (enzyme concentration 0.3 mg / ml) obtained in Example 3 of Korean Patent Publication No. 10-2021-0132405 (November 4, 2021) and the purified enzyme solution (enzyme concentration 0.3 mg / ml) obtained in Example 3 of this invention were heat-treated in a constant temperature water bath at 62°C for 0 hours, 0.5 hours, 1 hour, 1.5 hours, and 2 hours. Afterward, the heat-treated purified enzyme solution was added to a 50 mM piperazine-1,4-diethanesulfonic acid (PIPES) buffer solution (pH 7.0) containing 10% (w / w) fructose and 1 mM manganese sulfate (MnSO4) to achieve an enzyme concentration of 75 μg / ml. The reaction was carried out for 10 minutes at 62°C and 120 rpm using a shaking constant temperature water bath (VS-1205SW1, Vision Scientific). The reaction was then stopped by lowering the temperature of the reaction product to 4°C, and the supernatant was recovered by centrifugation at 16600×g and 4°C. The allulose and fructose concentrations in the supernatant were then determined using a high-performance liquid chromatography (HPLC) system (SP930D pump, Younglin equipment; MIDAS autosampler, SparkHolland) equipped with a sugar analysis column (Benson, USA) and a refractive index detector (2414 refractive index detector, Waters). The conversion rate from fructose to allulose was calculated from the results and used as an indicator of enzyme activity.

[0058] Table 4 below shows the conversion rate from fructose to allulose under different heat treatment conditions when the D-allulose 3-epimerase variant derived from *Flavonifractor plautii* is heat-treated.

[0059] Table 4

[0060]

[0061] As shown in Table 4 above, most of the newly synthesized D-allulose 3-epimerase variants derived from *Flavonifractor plautii*, based on the amino acid sequence of the variant W29K / G216S / M234I, exhibited lower fructose-to-allulose conversion activity and thermostability compared to W29K / G216S / M234I. On the other hand, the D-allulose 3-epimerase variant W29K / A77S / G216S / M234I showed similar or higher fructose-to-allulose conversion activity to the variant W29K / G216S / M234I, regardless of heat treatment time, and particularly exhibited significantly improved thermostability.

[0062] As described above, the present invention has been illustrated through the embodiments described above, but the present invention is not necessarily limited thereto, and various modifications can be made without departing from the scope and spirit of the present invention. Therefore, the scope of protection of the present invention should be interpreted to include all embodiments falling within the scope of protection of the appended patent claims. sequence list <110> Daesang Corporation <120> Allulose epimerase variant with excellent thermal stability, its preparation method, and the preparation method of allulose using it. <130> ZPCT-21-0119 <150> KR 10-2021-0160438 <151> 2021-11-19 <160> 12 <170> PatentIn version 3.5 <210> 1 <211> 294 <212> PRT <213> Artificial Sequence <220> <223> Wild type D-allulose 3-epimerase derived from Flavonifractor plautii <400> 1 Met Asn Pro Ile Gly Met His Tyr Gly Phe Trp Ser His Asn Trp Asp 1 5 10 15 Glu Ile Ala Tyr Ile Pro Leu Met Glu Lys Leu Ala Trp Leu Gly Phe 20 25 30 Asp Ile Cys Glu Val Ala Ser Ala Glu Trp Gly Tyr Tyr Asp Asp Ala 35 40 45 Arg Leu Arg Glu Leu Lys Ala Cys Ala Asp His Asn Gly Leu Gly Ile 50 55 60 Thr Tyr Ser Ile Gly Leu Glu Ala Lys Tyr Asp Leu Ala Ser Asp Asp 65 70 75 80 Pro Ala Val Arg Glu Asn Gly Ile Arg His Val Thr Arg Ile Leu Glu 85 90 95 Ser Met Pro Lys Val Gly Ala Ala Ile Leu Asn Gly Val Ser Tyr Ala 100 105 110 Gly Trp Gln Ala Leu Pro Asp His Gly Ile Thr Leu Asp Glu Lys Arg 115 120 125 Arg Lys Glu Glu Leu Ala Leu Glu Ser Met Ser Arg Leu Met Lys Val 130 135 140 Ala Glu Asp Cys Gly Val Leu Tyr Cys Cys Glu Val Val Asn Arg Phe 145 150 155 160 Glu Gln Tyr Leu Leu Asn Thr Ala Lys Glu Gly Val Glu Phe Val Lys 165 170 175 Arg Leu Gly Ser Pro Asn Ala Arg Val Leu Leu Asp Thr Phe His Met 180 185 190 Asn Ile Glu Glu Asp Ser Met Val Asp Ala Ile Leu Glu Ala Gly Pro 195 200 205 Trp Leu Gly His Phe His Val Gly Glu Asn Asn Arg Arg Pro Ala Gly 210 215 220 Ser Thr Asn Arg Leu Pro Trp Lys Asp Met Ala Ala Ala Leu Lys Gln 225 230 235 240 Val Asn Tyr Gln Gly Ala Ile Val Met Glu Pro Phe Val Leu Met Gly 245 250 255 Gly Thr Ile Pro Tyr Asp Ile Lys Val Trp Arg Asp Leu Ser Gly Gly 260 265 270 Ala Gly Glu Ala Gly Leu Asp Glu Met Ala Gly Arg Ala Cys Arg Phe 275 280 285 Leu Lys Glu Leu Thr Ala 290 <210> 2 <211> 885 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide coding wild type D-allulose 3-epimerase derived from Flavonifractor plautii <400> 2 atgaacccga ttggaatgca ctacggcttc tggagccaca actgggacga gattgcatac 60 atacccctga tggagaagct ggcctggctg ggctttgaca tctgcgaggt ggcctccgcc 120 gagtggggct attacgacga cgccaggctg cgggagctga aggcctgcgc cgatcacaac 180 ggcctgggca tcacctattc catcggcctg gaggccaaat acgacctggc cagcgacgat 240 ccggcggtgc gggagaacgg catccgccat gtcacccgca tcctggagag catgcccaag 300 gtgggggcgg ccatcctcaa cggcgtgtcc tacgccgggt ggcaggccct gccgaccac 360 ggaatcaccc tggacgagaa gcgccgcaag gaggagcttg ccctggagtc catgtcccgg 420 ctcatgaagg tggcggagga ctgcggcgtg ctctactgct gcgaggtggt caaccgcttc 480 gagcagtacc tgctcaacac cgccaaagag ggcgtggagt ttgtcaagcg cctgggcagt 540 cccaacgccc gggtgctgct ggataccttc cacatgaaca tcgaggagga cagcatggtg 600 gacgccattc tggaggcggg cccctggctg gggcatttcc acgtggggga gaacaaccgc 660 cgccccgccg gctccaccaa ccgcctgccc tggaaggaca tggccgccgc cctcaagcag 720 gtgaactacc agggggccat tgtgatggag cccttcgtgc tcatgggggg taccattccc 780 tatgatatca aggtctggcg ggatctcagc ggcggggccg gggaggccgg gctggacgag 840 atggcgggcc gggcctgccg gttcctcaag gagctgaccg cgtaa 885 <210> 3 <211> 294 <212> PRT <213> Artificial Sequence <220> <223> D-allulose 3-epimerase variant W29K / G216S / M234I <400> 3 Met Asn Pro Ile Gly Met His Tyr Gly Phe Trp Ser His Asn Trp Asp 1 5 10 15 Glu Ile Ala Tyr Ile Pro Leu Met Glu Lys Leu Ala Lys Leu Gly Phe 20 25 30 Asp Ile Cys Glu Val Ala Ser Glu Ala Trp Gly Tyr Tyr Asp Asp Ala 35 40 45 Arg Leu Arg Glu Leu Lys Ala Cys Ala Asp His Asn Gly Leu Gly Ile 50 55 60 Thr Tyr Ser Ile Gly Leu Glu Ala Lys Tyr Asp Leu Ala Ser Asp Asp 65 70 75 80 Pro Ala Val Arg Glu Asn Gly Ile Arg His Val Thr Arg Ile Leu Glu 85 90 95 Ser Met Pro Lys Val Gly Ala Ala Ile Leu Asn Gly Val Ser Tyr Ala 100 105 110 Gly Trp Gln Ala Leu Pro Asp His Gly Ile Thr Leu Asp Glu Lys Arg 115 120 125 Arg Lys Glu Glu Leu Ala Leu Glu Ser Met Ser Arg Leu Met Lys Val 130 135 140 Ala Glu Asp Cys Gly Val Leu Tyr Cys Cys Glu Val Val Asn Arg Phe 145 150 155 160 Glu Gln Tyr Leu Leu Asn Thr Ala Lys Glu Gly Val Glu Phe Val Lys 165 170 175 Arg Leu Gly Ser Pro Asn Ala Arg Val Leu Leu Asp Thr Phe His Met 180 185 190 Asn Ile Glu Glu Asp Ser Met Val Asp Ala Ile Leu Glu Ala Gly Pro 195 200 205 Trp Leu Gly His Phe His Val Ser Glu Asn Asn Arg Arg Pro Ala Gly 210 215 220 Ser Thr Asn Arg Leu Pro Trp Lys Asp Ile Ala Ala Ala Leu Lys Gln 225 230 235 240 Val Asn Tyr Gln Gly Ala Ile Val Met Glu Pro Phe Val Leu Met Gly 245 250 255 Gly Thr Ile Pro Tyr Asp Ile Lys Val Trp Arg Asp Leu Ser Gly Gly 260 265 270 Ala Gly Glu Ala Gly Leu Asp Glu Met Ala Gly Arg Ala Cys Arg Phe 275 280 285 Leu Lys Glu Leu Thr Ala 290 <210> 4 <211> 885 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide coding D-allulose 3-epimerase variant W29K / G216S / M234 <400> 4 atgaacccga ttggaatgca ctacggcttc tggagccaca actgggacga gattgcatac 60 atacccctga tggagaagct ggccaaactg ggctttgaca tctgcgaggt ggcctccgcc 120 gagtggggct attacgacga cgccaggctg cgggagctga aggcctgcgc cgatcacaac 180 ggcctgggca tcacctattc catcggcctg gaggccaaat acgacctggc cagcgacgat 240 ccggcggtgc gggagaacgg catccgccat gtcacccgca tcctggagag catgcccaag 300 gtgggggcgg ccatcctcaa cggcgtgtcc tacgccgggt ggcaggccct gcccgaccac 360 ggaatcaccc tggacgagaa gcgccgcaag gaggagcttg ccctggagtc catgtcccgg 420 ctcatgaagg tggcggagga ctgcggcgtg ctctactgct gcgaggtggt caaccgcttc 480 gagcagtacc tgctcaacac cgccaaagag ggcgtggagt ttgtcaagcg cctgggcagt 540 cccaacgccc gggtgctgct ggataccttc cacatgaaca tcgaggagga cagcatggtg 600 gacgccattc tggaggcggg cccctggctg gggcatttcc acgtgagcga gaacaaccgc 660 cgccccgccg gctccaccaa ccgcctgccc tggaaggaca ttgccgccgc cctcaagcag 720 gtgaactacc agggggccat tgtgatggag cccttcgtgc tcatgggggg taccattccc 780 tatgatatca aggtctggcg ggatctcagc ggcggggccg gggaggccgg gctggacgag 840 atggcgggcc gggcctgccg gttcctcaag gagctgaccg cgtaa 885 <210> 5 <211> 294 <212> PRT <213> Artificial Sequence <220> <223> D-allulose 3-epimerase variant W29K / A77S / G216S / M234I <400> 5 Met Asn Pro Ile Gly Met His Tyr Gly Phe Trp Ser His Asn Trp Asp 1 5 10 15 Glu Ile Ala Tyr Ile Pro Leu Met Glu Lys Leu Ala Lys Leu Gly Phe 20 25 30 Asp Ile Cys Glu Val Ala Ser Ala Glu Trp Gly Tyr Tyr Asp Asp Ala 35 40 45 Arg Leu Arg Glu Leu Lys Ala Cys Ala Asp His Asn Gly Leu Gly Ile 50 55 60 Thr Tyr Ser Ile Gly Leu Glu Ala Lys Tyr Asp Leu Ser Ser Asp Asp 65 70 75 80 Pro Ala Val Arg Glu Asn Gly Ile Arg His Val Thr Arg Ile Leu Glu 85 90 95 Ser Met Pro Lys Val Gly Ala Ala Ile Leu Asn Gly Val Ser Tyr Ala 100 105 110 Gly Trp Gln Ala Leu Pro Asp His Gly Ile Thr Leu Asp Glu Lys Arg 115 120 125 Arg Lys Glu Glu Leu Ala Leu Glu Ser Met Ser Arg Leu Met Lys Val 130 135 140 Ala Glu Asp Cys Gly Val Leu Tyr Cys Cys Glu Val Val Asn Arg Phe 145 150 155 160 Glu Gln Tyr Leu Leu Asn Thr Ala Lys Glu Gly Val Glu Phe Val Lys 165 170 175 Arg Leu Gly Ser Pro Asn Ala Arg Val Leu Leu Asp Thr Phe His Met 180 185 190 Asn Ile Glu Glu Asp Ser Met Val Asp Ala Ile Leu Glu Ala Gly Pro 195 200 205 Trp Leu Gly His Phe His Val Ser Glu Asn Asn Arg Arg Pro Ala Gly 210 215 220 Ser Thr Asn Arg Leu Pro Trp Lys Asp Ile Ala Ala Ala Leu Lys Gln 225 230 235 240 Val Asn Tyr Gln Gly Ala Ile Val Met Glu Pro Phe Val Leu Met Gly 245 250 255 Gly Thr Ile Pro Tyr Asp Ile Lys Val Trp Arg Asp Leu Ser Gly Gly 260 265 270 Ala Gly Glu Ala Gly Leu Asp Glu Met Ala Gly Arg Ala Cys Arg Phe 275 280 285 Leu Lys Glu Leu Thr Ala 290 <210> 6 <211> 294 <212> PRT <213> Artificial Sequence <220> <223> D-allulose 3-epimerase variant W29K / E173A / G216S / M234I <400> 6 Met Asn Pro Ile Gly Met His Tyr Gly Phe Trp Ser His Asn Trp Asp 1 5 10 15 Glu Ile Ala Tyr Ile Pro Leu Met Glu Lys Leu Ala Lys Leu Gly Phe 20 25 30 Asp Ile Cys Glu Val Ala Ser Ala Glu Trp Gly Tyr Tyr Asp Asp Ala 35 40 45 Arg Leu Arg Glu Leu Lys Ala Cys Ala Asp His Asn Gly Leu Gly Ile 50 55 60 Thr Tyr Ser Ile Gly Leu Glu Ala Lys Tyr Asp Leu Ala Ser Asp Asp 65 70 75 80 Pro Ala Val Arg Glu Asn Gly Ile Arg His Val Thr Arg Ile Leu Glu 85 90 95 Ser Met Pro Lys Val Gly Ala Ala Ile Leu Asn Gly Val Ser Tyr Ala 100 105 110 Gly Trp Gln Ala Leu Pro Asp His Gly Ile Thr Leu Asp Glu Lys Arg 115 120 125 Arg Lys Glu Glu Leu Ala Leu Glu Ser Met Ser Arg Leu Met Lys Val 130 135 140 Ala Glu Asp Cys Gly Val Leu Tyr Cys Cys Glu Val Val Asn Arg Phe 145 150 155 160 Glu Gln Tyr Leu Leu Asn Thr Ala Lys Glu Gly Val Ala Phe Val Lys 165 170 175 Arg Leu Gly Ser Pro Asn Ala Arg Val Leu Leu Asp Thr Phe His Met 180 185 190 Asn Ile Glu Glu Asp Ser Met Val Asp Ala Ile Leu Glu Ala Gly Pro 195 200 205 Trp Leu Gly His Phe His Val Ser Glu Asn Asn Arg Arg Pro Ala Gly 210 215 220 Ser Thr Asn Arg Leu Pro Trp Lys Asp Ile Ala Ala Ala Leu Lys Gln 225 230 235 240 Val Asn Tyr Gln Gly Ala Ile Val Met Glu Pro Phe Val Leu Met Gly 245 250 255 Gly Thr Ile Pro Tyr Asp Ile Lys Val Trp Arg Asp Leu Ser Gly Gly 260 265 270 Ala Gly Glu Ala Gly Leu Asp Glu Met Ala Gly Arg Ala Cys Arg Phe 275 280 285 Leu Lys Glu Leu Thr Ala 290 <210> 7 <211> 294 <212> PRT <213> Artificial Sequence <220> <223> D-allulose 3-epimerase variant W29K / W209L / G216S / M234I <400> 7 Met Asn Pro Ile Gly Met His Tyr Gly Phe Trp Ser His Asn Trp Asp 1 5 10 15 Glu Ile Ala Tyr Ile Pro Leu Met Glu Lys Leu Ala Lys Leu Gly Phe 20 25 30 Asp Ile Cys Glu Val Ala Ser Ala Glu Trp Gly Tyr Tyr Asp Asp Ala 35 40 45 Arg Leu Arg Glu Leu Lys Ala Cys Ala Asp His Asn Gly Leu Gly Ile 50 55 60 Thr Tyr Ser Ile Gly Leu Glu Ala Lys Tyr Asp Leu Ala Ser Asp Asp 65 70 75 80 Pro Ala Val Arg Glu Asn Gly Ile Arg His Val Thr Arg Ile Leu Glu 85 90 95 Ser Met Pro Lys Val Gly Ala Ala Ile Leu Asn Gly Val Ser Tyr Ala 100 105 110 Gly Trp Gln Ala Leu Pro Asp His Gly Ile Thr Leu Asp Glu Lys Arg 115 120 125 Arg Lys Glu Glu Leu Ala Leu Glu Ser Met Ser Arg Leu Met Lys Val 130 135 140 Ala Glu Asp Cys Gly Val Leu Tyr Cys Cys Glu Val Val Asn Arg Phe 145 150 155 160 Glu Gln Tyr Leu Leu Asn Thr Ala Lys Glu Gly Val Glu Phe Val Lys 165 170 175 Arg Leu Gly Ser Pro Asn Ala Arg Val Leu Leu Asp Thr Phe His Met 180 185 190 Asn Ile Glu Glu Asp Ser Met Val Asp Ala Ile Leu Glu Ala Gly Pro 195 200 205 Leu Leu Gly His Phe His Val Ser Glu Asn Asn Arg Arg Pro Ala Gly 210 215 220 Ser Thr Asn Arg Leu Pro Trp Lys Asp Ile Ala Ala Ala Leu Lys Gln 225 230 235 240 Val Asn Tyr Gln Gly Ala Ile Val Met Glu Pro Phe Val Leu Met Gly 245 250 255 Gly Thr Ile Pro Tyr Asp Ile Lys Val Trp Arg Asp Leu Ser Gly Gly 260 265 270 Ala Gly Glu Ala Gly Leu Asp Glu Met Ala Gly Arg Ala Cys Arg Phe 275 280 285 Leu Lys Glu Leu Thr Ala 290 <210> 8 <211> 294 <212> PRT <213> Artificial Sequence <220> <223> D-allulose 3-epimerase variant W29K / G216S / M234I / Q240D <400> 8 Met Asn Pro Ile Gly Met His Tyr Gly Phe Trp Ser His Asn Trp Asp 1 5 10 15 Glu Ile Ala Tyr Ile Pro Leu Met Glu Lys Leu Ala Lys Leu Gly Phe 20 25 30 Asp Ile Cys Glu Val Ala Ser Ala Glu Trp Gly Tyr Tyr Asp Asp Ala 35 40 45 Arg Leu Arg Glu Leu Lys Ala Cys Ala Asp His Asn Gly Leu Gly Ile 50 55 60 Thr Tyr Ser Ile Gly Leu Glu Ala Lys Tyr Asp Leu Ala Ser Asp Asp 65 70 75 80 Pro Ala Val Arg Glu Asn Gly Ile Arg His Val Thr Arg Ile Leu Glu 85 90 95 Ser Met Pro Lys Val Gly Ala Ala Ile Leu Asn Gly Val Ser Tyr Ala 100 105 110 Gly Trp Gln Ala Leu Pro Asp His Gly Ile Thr Leu Asp Glu Lys Arg 115 120 125 Arg Lys Glu Glu Leu Ala Leu Glu Ser Met Ser Arg Leu Met Lys Val 130 135 140 Ala Glu Asp Cys Gly Val Leu Tyr Cys Cys Glu Val Val Asn Arg Phe 145 150 155 160 Glu Gln Tyr Leu Leu Asn Thr Ala Lys Glu Gly Val Glu Phe Val Lys 165 170 175 Arg Leu Gly Ser Pro Asn Ala Arg Val Leu Leu Asp Thr Phe His Met 180 185 190 Asn Ile Glu Glu Asp Ser Met Val Asp Ala Ile Leu Glu Ala Gly Pro 195 200 205 Trp Leu Gly His Phe His Val Ser Glu Asn Asn Arg Arg Pro Ala Gly 210 215 220 Ser Thr Asn Arg Leu Pro Trp Lys Asp Ile Ala Ala Ala Leu Lys Asp 225 230 235 240 Val Asn Tyr Gln Gly Ala Ile Val Met Glu Pro Phe Val Leu Met Gly 245 250 255 Gly Thr Ile Pro Tyr Asp Ile Lys Val Trp Arg Asp Leu Ser Gly Gly 260 265 270 Ala Gly Glu Ala Gly Leu Asp Glu Met Ala Gly Arg Ala Cys Arg Phe 275 280 285 Leu Lys Glu Leu Thr Ala 290 <210> 9 <211> 885 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide coding D-allulose 3-epimerase variant W29K / A77S / G216S / M234I <400> 9 atgaacccga ttggaatgca ctacggcttc tggagccaca actgggacga gattgcatac 60 atacccctga tggagaagct ggccaaactg ggctttgaca tctgcgaggt ggcctccgcc 120 gagtggggct attacgacga cgccaggctg cgggagctga aggcctgcgc cgatcacaac 180 ggcctgggca tcacctattc catcggcctg gaggccaaat acgacctgag cagcgacgat 240 ccggcggtgc gggagaacgg catccgccat gtcacccgca tcctggagag catgcccaag 300 gtgggggcgg ccatcctcaa cggcgtgtcc tacgccgggt ggcaggccct gcccgaccac 360 ggaatcaccc tggacgagaa gcgccgcaag gaggagcttg ccctggagtc catgtcccgg 420 ctcatgaagg tggcggagga ctgcggcgtg ctctactgct gcgaggtggt caaccgcttc 480 gagcagtacc tgctcaacac cgccaaagag ggcgtggagt ttgtcaagcg cctgggcagt 540 cccaacgccc gggtgctgct ggataccttc cacatgaaca tcgaggagga cagcatggtg 600 gacgccattc tggaggcggg cccctggctg gggcatttcc acgtgagcga gaacaaccgc 660 cgccccgccg gctccaccaa ccgcctgccc tggaaggaca ttgccgccgc cctcaagcag 720 gtgaactacc agggggccat tgtgatggag cccttcgtgc tcatgggggg taccattccc 780 tatgatatca aggtctggcg ggatctcagc ggcggggccg gggaggccgg gctggacgag 840 atggcgggcc gggcctgccg gttcctcaag gagctgaccg cgtaa 885 <210> 10 <211> 885 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide encoding D-allulose 3-epimerase variant W29K / E173A / G216S / M234I <400> 10 atgaacccga ttggaatgca ctacggcttc tggagccaca actgggacga gattgcatac 60 atacccctga tggagaagct ggccaaactg ggctttgaca tctgcgaggt ggcctccgcc 120 gagtggggct attacgacga cgccaggctg cgggagctga aggcctgcgc cgatcacaac 180 ggcctgggca tcacctattc catcggcctg gaggccaaat acgacctggc cagcgacgat 240 ccggcggtgc gggagaacgg catccgccat gtcacccgca tcctggagag catgcccaag 300 gtgggggcgg ccatcctcaa cggcgtgtcc tacgccgggt ggcaggccct gccgaccac 360 ggaatcaccc tggacgagaa gcgccgcaag gaggagcttg ccctggagtc catgtcccgg 420 ctcatgaagg tggcggagga ctgcggcgtg ctctactgct gcgaggtggt caaccgcttc 480 gagcagtacc tgctcaacac cgccaaagag ggcgtggcgt ttgtcaagcg cctgggcagt 540 cccaacgccc gggtgctgct ggataccttc cacatgaaca tcgaggagga cagcatggtg 600 gacgccattc tggaggcggg cccctggctg gggcatttcc acgtgagcga gaacaaccgc 660 cgccccgccg gctccaccaa ccgcctgccc tggaaggaca ttgccgccgc cctcaagcag 720 gtgaactacc agggggccat tgtgatggag cccttcgtgc tcatgggggg taccattccc 780 tatgatatca aggtctggcg ggatctcagc ggcggggccg gggaggccgg gctggacgag 840 atggcgggcc gggcctgccg gttcctcaag gagctgaccg cgtaa 885 <210> 11 <211> 885 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide encoding D-allulose 3-epimerase variant W29K / W209L / G216S / M234I <400> 11 atgaacccga ttggaatgca ctacggcttc tggagccaca actgggacga gattgcatac 60 atacccctga tggagaagct ggccaaactg ggctttgaca tctgcgaggt ggcctccgcc 120 gagtggggct attacgacga cgccaggctg cgggagctga aggcctgcgc cgatcacaac 180 ggcctgggca tcacctattc catcggcctg gaggccaaat acgacctggc cagcgacgat 240 ccggcggtgc gggagaacgg catccgccat gtcacccgca tcctggagag catgcccaag 300 gtgggggcgg ccatcctcaa cggcgtgtcc tacgccgggt ggcaggccct gcccgaccac 360 ggaatcaccc tggacgagaa gcgccgcaag gaggagcttg ccctggagtc catgtcccgg 420 ctcatgaagg tggcggagga ctgcggcgtg ctctactgct gcgaggtggt caaccgcttc 480 gagcagtacc tgctcaacac cgccaaagag ggcgtggagt ttgtcaagcg cctgggcagt 540 cccaacgccc gggtgctgct ggataccttc cacatgaaca tcgaggagga cagcatggtg 600 gacgccattc tggaggcggg ccccctgctg gggcatttcc acgtgagcga gaacaaccgc 660 cgccccgccg gctccaccaa ccgcctgccc tggaaggaca ttgccgccgc cctcaagcag 720 gtgaactacc agggggccat tgtgatggag cccttcgtgc tcatgggggg taccattccc 780 tatgatatca aggtctggcg ggatctcagc ggcggggccg gggaggccgg gctggacgag 840 atggcgggcc gggcctgccg gttcctcaag gagctgaccg cgtaa 885 <210> 12 <211> 885 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide encoding D-allulose 3-epimerase variant W29K / G216S / M234I / Q240D <400> 12 atgaacccga ttggaatgca ctacggcttc tggagccaca actgggacga gattgcatac 60 atacccctga tggagaagct ggccaaactg ggctttgaca tctgcgaggt ggcctccgcc 120 gagtggggct attacgacga cgccaggctg cgggagctga aggcctgcgc cgatcacaac 180 ggcctgggca tcacctattc catcggcctg gaggccaaat acgacctggc cagcgacgat 240 ccggcggtgc gggagaacgg catccgccat gtcacccgca tcctggagag catgcccaag 300 gtgggggcgg ccatcctcaa cggcgtgtcc tacgccgggt ggcaggccct gccgaccac 360 ggaatcaccc tggacgagaa gcgccgcaag gaggagcttg ccctggagtc catgtcccgg 420 ctcatgaagg tggcggagga ctgcggcgtg ctctactgct gcgaggtggt caaccgcttc 480 gagcagtacc tgctcaacac cgccaaagag ggcgtggagt ttgtcaagcg cctgggcagt 540 cccaacgccc gggtgctgct ggataccttc cacatgaaca tcgaggagga cagcatggtg 600 gacgccattc tggaggcggg cccctggctg gggcatttcc acgtgagcga gaacaaccgc 660 cgccccgccg gctccaccaa ccgcctgccc tggaaggaca ttgccgccgc cctcaaggat 720 gtgaactacc agggggccat tgtgatggag cccttcgtgc tcatgggggg taccattccc 780 tatgatatca aggtctggcg ggatctcagc ggcggggccg gggaggccgg gctggacgag 840 atggcgggcc gggcctgccg gttcctcaag gagctgaccg cgtaa 885

Claims

1. An allulose epimerase variant, characterized in that, The amino acid sequence of the allulose epimerase variant is shown in SEQ ID NO:

5.

2. A polynucleotide, characterized in that, The allulose epimerase variant of claim 1 is encoded.

3. The polynucleotide according to claim 2, characterized in that, The nucleotide sequence of the polynucleotide is shown in SEQ ID NO:

9.

4. A recombinant vector, characterized in that, It comprises the polynucleotide as described in claim 2.

5. A recombinant bacterial strain, characterized in that, Transformation is performed using one of the polynucleotides described in claim 2, claim 3, or claim 4.

6. A method for preparing an allulose epimerase variant, characterized in that, include: The step of culturing the recombinant strain of claim 5 to express the allulose dimorphic isomerase variant; as well as The steps for isolating allulose epimerase variants from the fragments of recombinant strains expressing the above-mentioned allulose epimerase variants.

7. A composition for the production of allulose, characterized in that, It includes the allulose epimerase variant as described in claim 1.

8. A composition for the production of allulose, characterized in that, It includes the recombinant strain of claim 5, a culture of the recombinant strain, or a fragment of the recombinant strain.

9. A method for preparing allulose, characterized in that, The step includes reacting fructose with the allulose epimerase variant of claim 1 or a composition containing the allulose epimerase variant described above.

10. A method for preparing allulose, characterized in that, The step includes reacting fructose with the recombinant strain of claim 5, a culture of the recombinant strain, a fragment of the recombinant strain, or a composition containing one or more of these.

Citation Information

Patent Citations

  • Composition for converting fructose into psicose, and method for producing psicose using the same

    KR1020140021974A

  • Variant of D-allulose 3-epimerase, manufacturing method thereof and manufacturing method of D-alluose using the same

    KR1020210132405A

  • Variant of D-allulose 3-epimerase, manufacturing method thereof and manufacturing method of D-alluose using the same

    KR102254411B1

  • Psicose epimerase expression cassette and psicose preparation method using same

    CN119842773A

  • Thermostable D-psicose 3-epimerase as well as preparation method and application thereof

    CN121204038A